Extrait

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.

Critère d'inclusion

• B-cell Acute Lymphoblastic Leukemia,Relapsed B-cell Acute Lymphoblastic Leukemia,Refractory B-cell Acute Lymphoblastic Leukemia

Liens

• nct
• ictrp